Sponsor

Effector Therapeutics

Clinical research sponsor

Published trials6

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

6 shown

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)NCT04622007 · lead sponsor · 2021-06-02

UNKNOWN

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate CancerNCT03690141 · lead sponsor · 2018-11-27

TERMINATED

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCCNCT03318562 · lead sponsor · 2017-11-21

TERMINATED

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid TumorsNCT02605083 · lead sponsor · 2015-12-03

TERMINATED

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerNCT05101564 · collaborator · 2023-03-20

COMPLETED

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast CancerNCT04261218 · collaborator · 2020-08-25

COMPLETED

Sponsor roles

lead sponsor4

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.